|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||84.65 - 86.06|
|52 Week Range||68.65 - 98.00|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||16.09|
|Forward Dividend & Yield||3.08 (3.55%)|
|Ex-Dividend Date||Mar. 03, 2020|
|1y Target Est||N/A|
A subsidiary of the pharmaceutical giant will soon ramp up production of the nonprofit hospital's SARS-CoV-2 vaccine candidate, which has yet to enter human clinical trials.
Q1 GDP, Durable Goods and, of course, Initial Jobless Claims all hit the tape an hour before the bell, along with a new COVID-19 vaccine candidate and an executive order on social media.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
The hydroxychloroquine debate is far from over, as the drug gets qualified support from others deeply involved in the war against the coronavirus.
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
Clinical Professor of Epidemiology at NYU School of Global Public Health Dr. Robyn Gershon joins Yahoo Finance’s Seana Smith to discuss the latest coronavirus developments as more states gear up to implement reopening plans.
Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's recently approved drug for adults and children age 12 and older with sickle cell disease. The Food and Drug Administration (FDA) approved Oxbryta on Nov. 25., three months before the FDA's Priority Review action date for the decision.
The pan-European STOXX 600 <.STOXX> closed up 1.7% on largely broad-based gains. A 40% jump in first-quarter profit for UBS <UBSG.S>, the world's largest wealth manager, and a 4.2% in Spain's Santander <SAN.MC> despite an 82% slump in quarterly net profit lifted Europe's battered banking sector <.SX7P> to its highest point in two weeks. UK-based HSBC Holdings Plc's shares <HSBA.L> rallied 1% but it warned of more earnings pain ahead as it set aside a hefty $3 billion in bad loan provisions due to the COVID-19 pandemic.
Novartis <NOVN.S> saw first-quarter sales climb as hospitals and patients stocked up on drugs to avoid being left short during the coronavirus crisis, lifting profits for the Swiss drugmaker. The result topped Novartis's 2020 forecast of mid to high single-digit percentage growth for revenue and high single-digit to low double-digit growth for operating profit. "We assume Q2 healthcare systems return to normal operations, and with that we can come back to our originally planned performance in 2020," Narasimhan told reporters on a call.
United Way Centraide Canada & Food Banks Canada to receive donations through the Novartis Pharmaceuticals Canada Inc. and Sandoz Canada Inc. program Special fund created for organizations supporting COVID-19 ...
The U.S. death toll and COVID-19 cases climbed, as arguments flared over coronavirus treatments and the path to restarting the economy.
PHOENIX, April 20, 2020 /CNW/ -- Amblyotech, a US-based digital therapeutics company, announced that it has completed the sale of all of its outstanding shares to Novartis pursuant to a Share Purchase Agreement entered into between each shareholder of Amblyotech and Novartis. After the acquisition, Novartis intends to pursue the development of Amblyotech's novel digital technology for the treatment of amblyopia, also known as "lazy eye."
DORVAL, QC, April 15, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. is proud to announce that the company has been named to the 2020 list of Best Workplaces™ in Canada. The ranking has been made possible thanks to feedback from Canada-based employees across the Novartis businesses. Associates from the Novartis Innovative Medicines Division (Pharmaceuticals and Oncology business units), as well as Sandoz Canada weighed in, contributing to the prestigious ranking.
The Food and Drug Administration approved the anecdotally promising malaria drug for emergency use to treat hospitalized patients for Covid-19.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Novartis <NOVN.S> has found alternate transport options for its cell therapy Kymriah to address potential disruptions from European travel restrictions ordered by U.S. President Donald Trump this week in response to the coronavirus epidemic. The Swiss drugmaker said on Friday it does not foresee Kymriah supply issues at this time. Novartis has been shipping immune cells from European cancer patients receiving its so-called CAR-T therapy for re-engineering at one of its laboratories in New Jersey.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG.
Reuters is reporting that President Trump will meet with Treasury Secretary Steven Mnuchin and others to discuss potential fiscal policy responses to the coronavirus. Yahoo Finance’s Rick Newman joins Zack Guzman, Brian Cheung and Morning Brew Business Editor and Podcast Host Kinsey Grant on YFi PM.